Breaking News, Collaborations & Alliances

Roche, Manifold Bio Sign $2B Deal to Develop Next-Gen Brain Shuttles

Will utilize Manifold’s mDesign drug discovery engine and tissue-targeting shuttle portfolio to create blood-brain barrier shuttles for multiple brain-targeted therapeutic modalities.

Author Image

By: Charlie Sternberg

Associate Editor

Roche Holding AG has entered into a strategic research collaboration and licensing agreement with Manifold Bio, a Boston-based biotechnology firm specializing in AI-guided drug discovery and in vivo measurement technologies. The partnership aims to develop next-generation blood-brain barrier (BBB) shuttles to enhance delivery of therapeutics for neurological and neurodegenerative diseases. Under the terms of the agreement, Manifold will receive an upfront payment of $55 million and is eligibl...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters